Clinical Trials Logo
  1. Home
  2. Sialorrhea
  3. NCT05097079

Efficacy and Safety Study of MYOBLOC® in the Treatment of Sialorrhea in Pediatric Subjects

Sialorrhea Clinical Trial

Official title:
A Phase 3 Multicenter, Randomized, Double-Blind, Placebo-Controlled, Single-Treatment Efficacy and Safety Study of MYOBLOC® for the Treatment of Chronic Sialorrhea in Pediatric Subjects

Clinical Trial Summary

This study will evaluate the efficacy and safety of MYOBLOC for the Treatment of Chronic Sialorrhea in Pediatric Subjects.

Clinical Trial Description

This is a Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Study of the Efficacy and Safety of MYOBLOC in Pediatric Subjects. ;

Study Design

Related Conditions & MeSH terms

Clinical Trial Details
NCT number NCT05097079
Study type Interventional
Source Supernus Pharmaceuticals, Inc.
Contact Joseph T Hull, PhD
Phone (240) 403-5324
Email jhull@supernus.com
Status Not yet recruiting
Phase Phase 3
Start date November 30, 2023
Completion date March 30, 2024
View Details
See also
  Status Clinical Trial Phase
Completed NCT02425176 - Botulinum Toxin-A for Sialorrhoea Treatment in Asian Adults With Neurological Diseases Phase 2/Phase 3
Completed NCT02610868 - Open-Label and Single-Arm Study of MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adults Phase 3
Active, not recruiting NCT05164367 - Pharmacokinetics of Atropine Oral Gel Early Phase 1
Completed NCT01994109 - Efficacy and Safety Study of MYOBLOC® Followed by Open-Label Multiple-Treatment With MYOBLOC® in the Treatment of Troublesome Sialorrhea in Adult Subjects Phase 3
Active, not recruiting NCT01489904 - Application of Botulinum Toxin Type A in Salivary Glands in the Treatment of Drooling in Patients With Cerebral Palsy Phase 2/Phase 3
Recruiting NCT04873115 - Double-blind, Placebo-controlled, Randomized Clinical Trial Comparing the Efficacy and Safety of Sialanar Plus orAl rehabiLitation Against Placebo Plus Oral Rehabilitation for chIldren and Adolescents With seVere Sialorrhoea and Neurodisabilties, Phase 4
Withdrawn NCT03704168 - Safety and Efficacy of Cryoablation in Management of Sialorrhea in Patients With Neurological Disorders N/A
Completed NCT01653132 - Incobotulinum Toxin A (Xeomin®) for Troublesome Sialorrhea in Parkinson's Disease (PD)/Parkinsonism Phase 2
Completed NCT00491894 - Safety and Efficacy Study of Oral Glycopyrrolate Liquid for the Treatment of Pathologic (Chronic Moderate to Severe) Drooling in Pediatric Patients 3 to 18 Years of Age With Cerebral Palsy or Other Neurologic Conditions Phase 3
Completed NCT04197037 - Prevalence of Sialorrhea in Patients Treated With Clozapine
Completed NCT06101160 - Botulinum Toxin Injection for Sialorrhea in Cerebral Palsy
Completed NCT01191398 - Effectiveness of Atropine and Glycopyrrolate to Reduce Hyper Salivation With Ketamine Sedation N/A
Completed NCT01118143 - Oral Health Literacy Tailored Communication N/A
Recruiting NCT02382198 - Study of Glycopyrrolate for Moderate-to-severe Sialorrhea in Parkinson's Disease Phase 2
Completed NCT00125203 - Study of Myobloc in the Treatment of Sialorrhea (Drooling) in Patients With Amyotrophic Lateral Sclerosis (ALS) Phase 2/Phase 3
Completed NCT02613494 - Clozapine-induced Hypersalivation - Feasibility Trial Phase 1/Phase 2
Not yet recruiting NCT03747536 - Ipratropium Bromide Spray as Treatment for Sialorrhea in Children Phase 2
Completed NCT01551940 - Toxin Treatment for Amyotrophic Lateral Sclerosis (ALS) Related Sialorrhea Phase 2
Completed NCT00683891 - FazaClo Outcomes in the Control of Schizophrenia (FOCUS) Study Survey N/A